Relationship between supersaturation and crystal inhibition in hypercalciuric rats

Kidney International

Volumn 51, Issue 3, 1997, Pages 640-645

  Asplin, John R ^a   Bushinsky, David A ^b   Singharetnam, Wijeyasekaran ^b   Riordon, Daniel ^b   Parks, Joan H ^b   Coe, Fredric L ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE; CALCIUM PHOSPHATE;

ANIMAL EXPERIMENT; ARTICLE; CRYSTALLIZATION; FEMALE; HYPERCALCIURIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STONE FORMATION; UROLITHIASIS;

EID: 0030933709     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.93     Document Type: Article

References (26)

1. FINLAYSON B: Physicochemical aspects of urolithiasis. Kidney Int 13:344-360, 1978
2. BUSHINSKY DA, FAVUS MJ: Mechanism of hypercalciuria in genetic hypercalciuric rats. Inherited defect in intestinal calcium transport. J Chem Invest 82:1585-1591, 1988
3. 3 in bone from genetic hypercalciuric rats. Am J Physiol (in press)
4. LI X, TEMBE V, HORWITZ GM, BUSHINSKY DA, FAVUS MJ: Increased intestinal vitamin D receptor in genetic hypercalciuric rats. J Clin Invest 91:661-667, 1993
5. BUSHINSKY DA, KIM M, SESSLER N, NAKAGAWA Y, COE FL: Increased urinary saturation and kidney calcium content in genetic hypercalciuria rats. Kidnet Int 45:58-65, 1994
6. BUSHINSKY DA, GRYNPAS MD, NILSSON EL, NAKAGAWA Y, COE FL: Stone formation in genetic hypercalciuric rats. Kidney Int 48:1705-1713, 1995
7. PAK CYC, HOLT K: Nucleation and growth of brushite and calcium oxalate in urine of stone formers. Metabolism 25:665-673, 1976
8. LIESKE JC, COE FL: Urinary inhibitors and renal stone formation, in Kidney Stones: Medical and Surgical Management, edited by COE FL, FAVUS MJ, PAK CYC, PARKS JH, PREMINGER GM, Philadelphia, Lippincott-Raven, 1996, p 65
9. ASPLIN J, DEGANELLO S, NAKAGAWA YN, COE FL: Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 261:F824-F830, 1991
10. SHIRAGA H, MIN W, VANDUSEN WJ, CLAYMEN MD, MINER D, TERREL CH, SHERBOTIE JR, FOREMAN JW, PRZYSIECKI C, NEILSON EG, HOYER JR: Inhibition of calcium oxalate crystal growth in vitro by uropontin: Another member of the aspartic acid-rich protein superfamily. Proc Nat Acad Sci USA 89:426-430, 1992
11. NAKAGAWA Y, ABRAM V, PARKS JH, LAU HS, KAWOOYA JK, COE FL: Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 76:1455-1462, 1985
12. HESS B, NAKAGAWA Y, COE FL: Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99-F106, 1989
13. HESS B, NAKAGAWA Y, PARKS JH, COE FL: Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569-F578, 1991
14. NICAR MJ, HILL K, PAK CY: A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism 32:906-910, 1983
15. FRANCIS MD, WEBB NC: Hydroxyapatite formation from a hydrated calcium monohydrogen phosphate precursor. Calc Tiss Res 6:335-342, 1971
16. NAKAGAWA Y, AHMED M, HALL SL, DEGANELLO S, COE FL: Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest 79:1782-1787, 1987
17. KIM M, SESSLER NE, TEMBE V, FAVUS MJ, BUSHINSKY DA: Response of genetic hypercalciuric rats to a low calcium diet. Kidney Int 43:189-196, 1993
18. BROWN CM, PURICH DL: Physical-chemical processes in kidney stone formation, in Disorders of Bone and Mineral Metabolism, edited by COE FL, FAVUS MJ, New York, Raven Press, 1992, p 613
19. HESS B, NAKAGAWA Y, COE FL: A new spectrophotometric method for measuring calcium oxalate monohydrate crystal aggregation in the absence of supersaturation: Inhibitory effects of urinary glycoproteins. Urol Res 17:149-150, 1989
20. SILVERMAN BW: Density Estimation for Statisitics and Data Analysis. London, Chapman and Hall, 1986
21. ITO H, COE FL: Acidic peptide and polyribonucleotide crystal growth inhibitors in human urine. Am J Physiol 233:F455-F463, 1977
22. YAMAGUCHI S, YOSHIOKA T, UTSUNOMIYA M, KOIDE T, OSAFUNE M, OKUYAMA A, SONODA T: Heparan sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization. Urol Res 21:187-192, 1993
23. ATMANI F, KHAN SR: Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res 23:95-101, 1995
24. WILSON JWL, WERNESS PG, SMITH LH: Inhibitors of crystal growth of hydroyapatite: A constant composition approach. J Urol 134:1255-1258, 1985
25. CRAWFORD MA, MILNE MD, SCRIBNER BH: The effects of changes in acid-base balance of urinary citrate in the rat. J Physiol 149:413-432, 1959
26. BRENNAN S, HERING-SMITH K, HAMM LL: Effect of pH on citrate reabsorption in the proximal convoluted tubule. Am J Physiol 255: F301-F306, 1988